Richards, Merrill & Peterson’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-100
Closed -$8.11K 479
2025
Q1
$8.11K Hold
100
﹤0.01% 415
2024
Q4
$9.01K Buy
+100
New +$9.69K ﹤0.01% 392

Other funds holding XBI

Richards, Merrill & Peterson's XBI Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 100 shares — an estimated $8.11K sold.

Richards, Merrill & Peterson first reported a position in XBI in Q4 2024 and held it in 2 quarters. The position peaked at $9.01K in Q4 2024. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 100 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $8.11K.
  • Richards, Merrill & Peterson first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's State Street SPDR S&P Biotech ETF position peaked at $9.01K in Q4 2024.
  • 625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.